利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.028 秒)

    Canine adenovirus vectors
    3.
    发明授权
    Canine adenovirus vectors 有权

    公开(公告)号：US10329586B2

    公开(公告)日：2019-06-25

    申请号：US15706898

    申请日：2017-09-18

    申请人： Boehringer Ingelheim Vetmedica GmbH

    发明人： Andreas Gallei ,  Ramesh Koukuntla ,  Robert Barry Mandell ,  Alice Mundt ,  Kristina Rehmet ,  Eric Martin Vaughn

    IPC分类号： C12N15/86 ,  A61K39/155 ,  A61K39/205 ,  A61K48/00 ,  A61K39/00

    摘要： The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.

    Vaccine against porcine parvovirus
    8.
    发明授权
    Vaccine against porcine parvovirus 有权

    公开(公告)号：US10799578B2

    公开(公告)日：2020-10-13

    申请号：US16598110

    申请日：2019-10-10

    申请人： Boehringer Ingelheim Vetmedica GmbH

    发明人： Scott Eugene Bucklin ,  Troy James Kaiser ,  Jeremy Kroll ,  Philip Utley ,  Eric Martin Vaughn

    IPC分类号： A61K39/23 ,  A61K39/12 ,  C07K14/005 ,  A61P31/20 ,  C12N7/00 ,  A61K39/00

    摘要： The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.